Atlas Trials

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

Clinical trial NCT02408913 · COMPLETED

Trial details

NCT number
NCT02408913
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy Adult Immune Responses to Vaccine
Start date
2015-03-26
Primary completion
2017-04-06
Enrollment
140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.